Namdari Nasrin, Haghpanah Sezaneh, Ataie Elahe, Ghanbarian Fateme, Mokhtari Maral, Amini Mahya
Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Int J Hematol Oncol Stem Cell Res. 2025 Apr 1;19(2):101-108. doi: 10.18502/ijhoscr.v19i2.18547.
: Acute-phase reactant proteins, particularly C-reactive protein (CRP), play a critical role in the initiation, progression, and recurrence of cancers such as acute myeloid leukemia. We retrospectively analyzed 127 newly diagnosed non-M3 acute myeloblastic leukemia (non-M3 AML) patients. We investigated pre-treatment levels of C-reactive protein (CRP), Albumin, and C-reactive protein to albumin ratio (CAR) with cytogenetics, response to induction therapy, recurrence, and overall survival. We did not find any relationship between levels of CRP, Albumin, and C-reactive protein to albumin ratio (CAR) with complete remission rate, recurrence, and risk categorization of patients (P > 0.05). 3-and 5- year overall survival was 40.8% (with a standard error of 4.7%) and 30.1% (standard error: 5.3%), respectively. In addition, 3-year and 5-year event-free survival was 31.3% (standard error = 4.4%) and 25.8% (standard error = 4.8%), respectively. The only prognostic factor was allogenic stem cell transplantation (SCT). Although CRP, Albumin, and CAR serve as convenient prognostic markers, they were not predictive of overall survival (OS) and event-free survival (EFS) in AML patients. Further studies are needed in the future to confirm or refute our results.
急性期反应蛋白，尤其是C反应蛋白（CRP），在急性髓系白血病等癌症的发生、发展和复发中起关键作用。我们回顾性分析了127例新诊断的非M3急性髓性白血病（非M3 AML）患者。我们研究了C反应蛋白（CRP）、白蛋白以及C反应蛋白与白蛋白比值（CAR）的预处理水平与细胞遗传学、诱导治疗反应、复发和总生存期的关系。我们未发现CRP、白蛋白水平以及C反应蛋白与白蛋白比值（CAR）与患者的完全缓解率、复发及风险分类之间存在任何关联（P>0.05）。3年和5年总生存率分别为40.8%（标准误为4.7%）和30.1%（标准误：5.3%）。此外，3年和5年无事件生存率分别为31.3%（标准误=4.4%）和25.8%（标准误=4.8%）。唯一的预后因素是异基因干细胞移植（SCT）。尽管CRP、白蛋白和CAR可作为方便的预后标志物，但它们并不能预测AML患者的总生存期（OS）和无事件生存期（EFS）。未来需要进一步研究以证实或反驳我们的结果。
